Novo Nordisk AS Newswire (Page 10)

Novo Nordisk AS Newswire (Page 10)

Comprehensive Real-Time News Feed for Novo Nordisk AS. (Page 10)

Results 181 - 200 of 1,478 in Novo Nordisk AS

  1. Announcing Morningstar's 2015 Fund Managers of the YearRead the original story

    Jan 26, 2016 | Morningstar

    Our manager research team at Morningstar analyzes and rates more than a thousand fund managers every year and speaks to hundreds more whose funds we don't cover. Over the years, we've come to appreciate how difficult it is for most active managers to perform consistently well using a repeatable, well-executed process.

    Comment?

  2. Rich Pipeline Assures Steady Pace Of Approvals In 2015Read the original story w/Photo

    Jan 26, 2016 | Seeking Alpha

    Investors searching for a reason for biotech market blues for once cannot point to lack of research and development productivity. Last year was another big one for FDA drug approvals, adding nearly $28bn in forecast sales five years after launch.

    Comment?

  3. Novo Nordisk A/S (NVO) Lifted to Buy at Oddo SecuritiesRead the original story w/Photo

    Jan 26, 2016 | AmericanBankingNews.com

    Other hedge funds have modified their holdings of the company. Reilly Financial Advisors LLC raised its stake in shares of Novo Nordisk A/S by 828.6% in the fourth quarter.

    Comment?

  4. Novo Nordisk A/S (NVO) Upgraded by Oddo Securities to "Buy"Read the original story w/Photo

    Jan 26, 2016 | AmericanBankingNews.com

    Shares of Novo Nordisk A/S traded down 0.76% on Tuesday, reaching $54.84. The company had a trading volume of 410,658 shares.

    Comment?

  5. Big Pharma's bet on Big Data creates opportunities and risksRead the original story w/Photo

    Jan 26, 2016 | West Australian

    The Swiss drugmaker has teamed up with U.S. technology firm Qualcomm to develop an internet-connected inhaler that can send information about how often it is used to remote computer servers known as the cloud. This kind of new medical technology is designed to allow patients to keep track of their drug usage on their smartphones or tablets and for their doctors to instantly access the data over the web to monitor their condition.

    Comment?

  6. Novo Nordisk A/S (NVO) Shares Bought by Augustine Asset ManagementRead the original story w/Photo

    Jan 26, 2016 | AmericanBankingNews.com

    Augustine Asset Management increased its position in shares of Novo Nordisk A/S by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission . The institutional investor owned 68,688 shares of the company's stock after buying an additional 1,038 shares during the period.

    Comment?

  7. New Speakers Confirmed at SMi's 2nd Annual Lyophilization USA...Read the original story w/Photo

    Jan 26, 2016 | PRWeb

    Due to four new speakers being added onto the agenda, SMi Group are delighted to announce that a new brochure has been released for the 2nd annual Lyophilization USA conference taking place on April 27th and 28th in Iselin, New Jersey. Those who have recently confirmed to present include Allergan, Genentech, Endo Pharmaceuticals and Parexel.

    Comment?

  8. EFMD is Delighted to Announce the Winners of the 2012 EFMD Case Writing CompetitionRead the original story w/Photo

    Feb 21, 2013 | 24-7 Press Release

    Winners include Copenhagen Business School, EMLYON, Rotterdam School of Management, IMD, INSEAD, CEIBS, Northeastern University, Indiana University Kelley School of Business, Richard Ivey School of Business, IESE & the University of Geneva. BRUSSELS, BELGIUM, February 21, 2013 /24-7PressRelease/ -- EFMD is delighted to announce the winners of the first phase of the 2012 EFMD Case Writing Competition.

    Comment?

  9. Novo aims to be ahead of pharma pack with Iran investmentRead the original story

    Jan 23, 2016 | Tehran Times

    Danish drugmaker Novo Nordisk, the world's top insulin supplier, expects to be ahead of the pack now nuclear sanctions are lifted in Iran, thanks to a continuous presence and a pre-emptive investment plan. The country is an attractive target for Big Pharma seeking to sell new medicines to its large and growing population, but going in at ground level and securing good relations with authorities will be key, industry executives say.

    Comment?

  10. Novo Nordisk A/S (NVO) Shares Bought by North American ManagementRead the original story w/Photo

    Jan 21, 2016 | AmericanBankingNews.com

    North American Management boosted its stake in Novo Nordisk A/S by 35.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 41,957 shares of the company's stock after buying an additional 11,027 shares during the period.

    Comment?

  11. Strade Bianche announces teams for 2016 raceRead the original story w/Photo

    Jan 21, 2016 | Velonews

    RCS Sport, organizer of the up-and-coming Strade Bianche classic race, announced Thursday the 18 teams invited to race on Tuscany's gravel roads this March. The 176km men's race will be contested by 12 WorldTour teams and six Pro Continental teams, March 5 in Sienna, Italy.

    Comment?

  12. Novo Nordisk: Saxenda Sales Start Off 2016 On Right TrackRead the original story w/Photo

    Jan 20, 2016 | Seeking Alpha

    Novo Nordisk is known as a giant in the diabetes sector and has used that muscle to work its way into the anti-obesity space, garnering approvals faster than others in the space and also garnering revenues that would make the anti-obesity pill players jealous. The biggest differentiator in the Novo Nordisk story with Saxenda is the size and abilities of the company to drive a market rather than wait for it and hope that it develops.

    Comment?

  13. Novo Nordisk: This Winner Has Risks, Be AwareRead the original story w/Photo

    Jan 19, 2016 | Seeking Alpha

    I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it .

    Comment?

  14. P. R. Herzig & Company Acquires Shares of 7,800 Novo Nordisk A/SRead the original story w/Photo

    Jan 19, 2016 | AmericanBankingNews.com

    P. R. Herzig & Company acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter, according to its most recent filing with the SEC. The institutional investor acquired 7,800 shares of the company's stock, valued at approximately $453,000.

    Comment?

  15. Giro d'Italia announces 2016 wildcards, includes Russia's Gazprom-RusVeloRead the original story w/Photo

    Jan 18, 2016 | Velonews

    The Giro d'Italia will continue its push abroad with a surprise move to invite Russia's Gazprom-RusVelo to the 2016 edition of the race. Race organizer RCS Sport announced Monday the four wildcard Pro Continental teams that will race alongside the 18 WorldTour teams from May 6-29.

    Comment?

  16. Novo Nordisk A/S (NVO) to Post FY2016 Earnings of $2.33 Per Share, Jefferies Group ForecastsRead the original story w/Photo

    Jan 18, 2016 | AmericanBankingNews.com

    Equities researchers at Jefferies Group raised their FY2016 earnings per share estimates for Novo Nordisk A/S in a report issued on Thursday, Zacks Investment Research reports. Jefferies Group analyst J. Holford now forecasts that the brokerage will post earnings of $2.33 per share for the year, up from their prior forecast of $2.27.

    Comment?

  17. Novo Nordisk A/S - Share repurchase programmeRead the original story w/Photo

    Jan 18, 2016 | GlobeNewswire

    BagsvA rd, Denmark, 18 January 2016 - On 29 October 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

    Comment?

  18. Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment ResearchRead the original story w/Photo

    Jan 17, 2016 | AmericanBankingNews.com

    's stock had its "sell" rating reissued by Zacks Investment Research in a research report issued to clients and investors on Sunday, MarketBeat.Com reports. According to Zacks, "Novo Nordisk's third-quarter 2015 results were strong with revenues increased on the back of robust performance from Victoza and Levemir as well as significant contributions from Tresiba and Saxenda.

    Comment?

  19. What Pharma/Biotech Investors Need To Know About Adaptive TrialsRead the original story w/Photo

    Jan 15, 2016 | Seeking Alpha

    The FDA allows for adaptive drug trials during which key protocols may be altered during the course of the trial depending on interim results. Investors concerned with pharmaceutical or biotech drug development, from early to late stages, need to be aware of the benefits and risks of adaptive trials because their use and interpretation can impact corporate valuations.

    Comment?

  20. Novo Nordisk A/S (NVO) is Norman Fields, Gottscho Capital Management's 9th Largest PositionRead the original story w/Photo

    Jan 15, 2016 | AmericanBankingNews.com

    Norman Fields, Gottscho Capital Management held its stake in shares of Novo Nordisk A/S during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The institutional investor owned 82,680 shares of the company's stock at the end of the fourth quarter.

    Comment?